[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vitamin D deficiency in the UK", "description": "1st October, Vitamin D, news and science\nhttps://www.youtube.com/watch?v=B01ZlRfMnmU\n\n16th September, Vitamin D and pandemic science\nhttps://www.youtube.com/watch?v=ZqZLMoLvhgk\n\n12th September, Vitamin D, Large scale studies\nhttps://www.youtube.com/watch?v=iNji13yoW9g\n\n6th September, Vitamin D, Frist clinical trial\nhttps://www.youtube.com/watch?v=V8Ks9fUh2k8\n\n27th July, Vitamin D, Science\nhttps://www.youtube.com/watch?v=cv4iINxf4IM\n\n20th June, Vitamin D hits the media\nhttps://www.youtube.com/watch?v=qyMFsLFAE5o\n\n10th June, Vitamin D update\nhttps://www.youtube.com/watch?v=_fIMkigtnk4\n\n18th May, Dr Shelton, Part 1, Reports from New Zealand\nhttps://www.youtube.com/watch?v=pRd7TqqIxzg&t=1s\n\n21st May, Dr Shelton, Part 2, Vitamin D\nhttps://www.youtube.com/watch?v=JVg8opQkQXc\n\n10th May, Vitamin D dose\nhttps://www.youtube.com/watch?v=Bga_qG30JyY\n\n15th April, Vitamin D and Immunity, Lots of evidence\nhttps://www.youtube.com/watch?v=GCSXNGc7pfs\n\n9th March, Vitamin D and immunity\nhttps://www.youtube.com/watch?v=W5yVGmfivAk\n\nThere is not enough evidence that vitamin D supplements protect people against Covid-19, an expert panel says.\n\nhttps://www.bbc.co.uk/news/health-55333063?fbclid=IwAR1ifnBFl42oj0uAcF1B-rfXONU8qnsHVIPpjpHIuIG7VK7poO0DOaCUZEk\n\nInstitute for Health and Care Excellence\n\nPublic Health England \n\nScientific Advisory Committee on Nutrition\n\nMore research needed\n\nInsufficient evidence\n\nAdvised to take a daily supplement this winter to keep bones and muscles healthy\n\n10 micrograms (400 international units)\n\nNobel prize, 1928, Adolf Windaus \n\nDr Paul Chrisp\n\nWe are continuing to monitor evidence as it is published and will review and update the guidance if necessary\n\nDeterminants of vitamin D deficiency in the UK (Clinical Nutrition)\n\nUniversity of South Australia (16th December)\n\nhttps://www.clinicalnutritionjournal.com/article/S0261-5614(20)30639-7/fulltext#%20\n\nhttps://www.clinicalnutritionjournal.com/article/S0261-5614(20)30639-7/fulltext\n\nhttps://www.unisa.edu.au/Media-Centre/Releases/2020/alarmingly-high-vitamin-d-deficiency-in-the-united-kingdom/\n\nUsing UK Biobank data\n\nhttps://www.ukbiobank.ac.uk\n\nSevere vitamin D deficiency remains an issue throughout the UK\n\nCross-ethnic analyses on the prevalence and determinants of vitamin D deficiency\n\n25(OH)D equal to or less than 25 nmol/L       Calcifediol\n\n10 ng/ml\n\nData from 440,581 UK Biobank participants\n\n415,903 identified as White European\n\n7,880 Asian\n\n7,602 Black African\n\n1,383 Chinese\n\n6,473 of mixed ancestry\n\nPrevalence of vitamin D deficiency\n\nAsian ancestry\n\n57.2% in winter or spring\n\n50.8% in summer or autumn\n\nBlack African ancestry\n\n38.5% in winter and spring\n\n30.8% in summer or autumn\n\nMixed ancestry\n\n36.5% in winter and spring\n\n22.5% in summer or autumn\n\nChinese ancestry\n\n33.1% in winter and spring\n\n20.7% in summer or autumn\n\nWhite European ancestry\n\n17.5% in winter and spring\n\n5.9% in summer or autumn\n\nParticipants with higher socioeconomic deprivation\n\nMore likely to have 25(OH)D deficiency compared to less deprived participants (P =  less than 1 \u00d7 10 \u2212300)\n\nThis pattern was more apparent among those of White European ancestry\n\nRegular consumption of oily fish was associated with reduced odds of vitamin D deficiency across all ethnicities\n\nAsians are less likely to eat fish or use vitamin D supplements compared to other ethnicities\n\nOutdoor-time in summer was less effective for Black Africans than White Europeans\n\nOther risk factors\n\nLiving further north\n\nIndoor employment\n\nComputer time and games\n\nProfessor Elina Hypponen (SA)\n\nThe severity of vitamin D deficiency is concerning\n\nespecially with the high rates of COVID-19 infections in Europe and elsewhere in the northern hemisphere this winter\n\nClinical trials have shown that vitamin D supplements are beneficial in the prevention of respiratory infections and even mortality\n\nVitamin D is not expensive and the doses which have shown the greatest benefits are those that we can all acquire over the counter from the local pharmacy\n\nGiven the COVID-19 pandemic, now is really the time for all who may be affected to take action", "link": "https://www.youtube.com/watch?v=Qwaq4oRnpjY", "date_published": "2020-12-17 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Live lesson with Tanzania", "description": "Tanzania, Live Q and A\n\nWith Doctor Nasibu Mwande\n\nJohn\u2019s introduction 0 \u2013 10 minutes\n\nDo mRNA vaccines effect human DNA? 10 mins\n\nDoes the vaccine confer immunity on all ethnic groups? 12 mins\n\nWill mRNA vaccines cause human mutations? 16 mins\n\nDo vaccines carry a secret code that can track people? 22 mins\n\nDid the UK authorise the Oxford vaccine too quickly? 26 mins\n\nIs the vaccine safe for children? 32 mins\n\nWhat about the dose for the Oxford vaccine? 45 mins\n\nWhat is the dose for vitamin D? 53 mins", "link": "https://www.youtube.com/watch?v=jGpit7vMSoA", "date_published": "2020-12-16 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Update, Wed 16 Dec", "description": "UK \n\nChristmas rules\n\nGermany\n\nDeaths, + 935\n\nSchools\n\nNon-essential businesses\n\nuntil 10 January\n\nOne household, four close family members\n\nFrance\n\nCurfew\n\nBars and restaurants closed until 20 January\n\nSpain\n\nhttps://www.theguardian.com/world/live/2020/dec/15/coronavirus-live-news-netherlands-announces-five-week-lockdown-as-uk-detects-new-covid-strain\n\n10% antibody study shows\n\nN = 51,400\n\nSecond half of November\n\nRaquel Yotti, Carlos III health institute\n\nOne in 10 people living in Spain would have been infected ... half during the first wave and the other half during this second epidemic wave\n\nMadrid, 18.6% \n\nPrevious results of the study - published in July after testing nearly 70,000 people in \n\nApril-June, prevalence 5.2 %.\n\nDeaths, + 388 = 48,401\n\nPositive test results, + 10,328 = 1,762,212\n\nPopulation = 47 million\n\nCases, 4.7 million\n\nCFR = 2.7%\n\nIFR = 1.02%\n\nModerna / NIH\n\nFood and Drug Administration scientists\n\nhttps://www.fda.gov/media/144434/download\n\n54 page document\n\nTwo-shot regimen was highly effective, 94%\n\nPrevents infections and symptoms\n\nNo serious safety concerns\n\nFriday, 18th \n\nGeneral Gustave Perna\n\nCambridge, Massachusetts, \"vast majority\" \n\nPreparing to ship almost 6 million doses\n\n3,285 locations in the first week\n\nUS, 20 million then 200 million\n\nIt will be a very similar cadence that was executed this week with Pfizer, where we\u2019re hitting initial sites on Monday, follow on Tuesday and Wednesday\n\nCanada, 168,000 this year, 56 million by March\n\nUK, 7 million\n\nEuropean Union, 80m + 80m\n\nJapan, 50m\n\nSouth Korea, 20m\n\nSwitzerland, 7.5m\n\nVaccine progress\n\nMHRA, 1\n\n137,000 in first week\n\nFDA, 2\n\nHC, 1\n\nEMA, 0\n\nSecond peer reviewed vaccine study\n\nSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=featured_home\n\nOngoing multinational\n\nPlacebo-controlled, observer-blinded, randomised, efficacy trial\n\n16 years or older\n\nOne to one\n\nTwo doses, 21 days apart\n\nPlacebo or the BNT162b2 vaccine\n\n30 \u03bcg per dose\n\nLipid nanoparticle\n\nModified RNA vaccine\n\nEncodes a membrane-anchored SARS-CoV-2 full-length spike protein\n\nn = 43,448 received injections\n\nBNT162b2 group, n = 21,720\n\n8 cases of COVID, at least 7 days after the second dose\n\n1 severe\n\nPlacebo group, n = 21,782\n\n162 cases\n\n9 severe\n\n95% (90.3 to 97.6)\n\nOctober 9\n\nN = 37,706 with at least 2 months of safety data\n\n49% were female, \n\n83% were white, \n\n9% were Black or African American, \n\n28% were Hispanic or Latino \n\n35% were obese, of at least 30.0\n\n21% had at least one coexisting condition\n\nMedian age, 52 years\n\n42% older than 55 years\n\nSafety profile\n\nShort-term, mild-to-moderate pain at the injection site, fatigue, and headache\n\nSafety over a median of 2 months was similar to that of other viral vaccines. \n\nSystemic events, most common after 2nd dose\n\nResolved after 1 \u2013 2 days\n\nFatigue and headache, 55%\n\nPlacebo fatigue and headache, 23%\n \nFever, mostly after 2nd dose\n\nTemperature, equal or greater than 38\u00b0C\n\n16% of younger recipients\n\n11% of older recipients\n\nIncidence of serious adverse events was low and was similar in the vaccine and placebo groups\n\nNo stopping rules were met", "link": "https://www.youtube.com/watch?v=wb_0FB7XiqA", "date_published": "2020-12-16 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]